Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vera Therapeutics, Inc. - Class A Common Stock (NQ:VERA)

38.86 -1.40 (-3.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 763,192
Open 39.88
Bid (Size) 30.00 (100)
Ask (Size) 40.00 (300)
Prev. Close 40.26
Today's Range 38.16 - 40.47
52wk Range 18.53 - 56.05
Shares Outstanding 44,261,109
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
From Vera Therapeutics
Via GlobeNewswire

Performance

YTD
-20.1%
-20.1%
1 Month
-6.8%
-6.8%
3 Month
-27.5%
-27.5%
6 Month
+37.8%
+37.8%
1 Year
+46.5%
+46.5%

More News

Read More
News headline image
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish ↗
Via The Motley Fool
News headline image
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year ↗
Via The Motley Fool
News headline image
This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock ↗
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
News headline image
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vertex Pharmaceuticals Surges 8.3% as Renal Breakthrough Sparks Market Rally
Via MarketMinute
Topics Stocks
News headline image
Vertex Pharmaceuticals Surges as Breakthrough Kidney Data Sets New Gold Standard for IgA Nephropathy
Via MarketMinute
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Appoints Christopher Hite to Board of Directors
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Participate at Upcoming Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
News headline image
Why Vera Therapeutics Stock Zoomed Higher Today ↗
Via The Motley Fool
News headline image
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Vera Therapeutics, Inc. - Class A Common Stock publicly traded?
Yes, Vera Therapeutics, Inc. - Class A Common Stock is publicly traded.
What exchange does Vera Therapeutics, Inc. - Class A Common Stock trade on?
Vera Therapeutics, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vera Therapeutics, Inc. - Class A Common Stock?
The ticker symbol for Vera Therapeutics, Inc. - Class A Common Stock is VERA on the Nasdaq Stock Market
What is the current price of Vera Therapeutics, Inc. - Class A Common Stock?
The current price of Vera Therapeutics, Inc. - Class A Common Stock is 38.86
When was Vera Therapeutics, Inc. - Class A Common Stock last traded?
The last trade of Vera Therapeutics, Inc. - Class A Common Stock was at 03/27/26 04:00 PM ET
What is the market capitalization of Vera Therapeutics, Inc. - Class A Common Stock?
The market capitalization of Vera Therapeutics, Inc. - Class A Common Stock is 1.72B
How many shares of Vera Therapeutics, Inc. - Class A Common Stock are outstanding?
Vera Therapeutics, Inc. - Class A Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.